Ann: New Independent Trial Data Supports Potential of Veyonda, page-20

The LuPIN study was set up to see if Veyonda could tip the balance and improve response rates, and to do so safely. One of the key outcomes being looked at was whether Veyonda could help patients complete their full course of 177Lu-PSMA therapy. ¹⁷⁷Lu-PSMA injections are spaced 6-weeks apart. Some groups give a course of 4 injections over 5 months, others up to 6 injections over 8 months. Patients continue to receive the injections providing that their PSA levels indicate that the cancer is continuing to respond to treatment. The injections stop once the PSA levels start rising or their general symptoms worsen.

In other words, the longer the patient can continue to stay on ¹⁷⁷Lu-PSMA therapy (5-8 months), the better their response, and the more likely they are to have a better outcome.

See: A comment on 177Lu-PSMA therapy and the LuPIN study data (noxopharm.com)